313 related articles for article (PubMed ID: 27662014)
1. Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.
Cao W; Pham HP; Williams LA; McDaniel J; Siniard RC; Lorenz RG; Marques MB; Zheng XL
Haematologica; 2016 Nov; 101(11):1319-1326. PubMed ID: 27662014
[TBL] [Abstract][Full Text] [Related]
2. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.
Staley EM; Cao W; Pham HP; Kim CH; Kocher NK; Zheng L; Gangaraju R; Lorenz RG; Williams LA; Marques MB; Zheng XL
Haematologica; 2019 Jan; 104(1):166-175. PubMed ID: 30171022
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
4. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
Zheng XL; Wu HM; Shang D; Falls E; Skipwith CG; Cataland SR; Bennett CL; Kwaan HC
Haematologica; 2010 Sep; 95(9):1555-62. PubMed ID: 20378566
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura.
Mikes B; Sinkovits G; Farkas P; Csuka D; Schlammadinger A; Rázsó K; Demeter J; Domján G; Réti M; Prohászka Z
Thromb Res; 2014 Apr; 133(4):616-21. PubMed ID: 24548690
[TBL] [Abstract][Full Text] [Related]
6. Current management of thrombotic thrombocytopenic purpura.
Kremer Hovinga JA; Meyer SC
Curr Opin Hematol; 2008 Sep; 15(5):445-50. PubMed ID: 18695366
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
8. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.
Yarranton H; Machin SJ
Curr Opin Neurol; 2003 Jun; 16(3):367-73. PubMed ID: 12858075
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
Pecoraro C; Ferretti AV; Rurali E; Galbusera M; Noris M; Remuzzi G
Am J Kidney Dis; 2015 Dec; 66(6):1067-70. PubMed ID: 26409664
[TBL] [Abstract][Full Text] [Related]
10. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Kato S; Fujimura Y
Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
[TBL] [Abstract][Full Text] [Related]
11. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies.
Farkas P; Csuka D; Mikes B; Sinkovits G; Réti M; Németh E; Rácz K; Madách K; Gergely M; Demeter J; Prohászka Z
Immunobiology; 2017 Feb; 222(2):119-127. PubMed ID: 27771173
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
Starke R; Machin S; Scully M; Purdy G; Mackie I
Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic thrombocytopenic purpura: a moving target.
Sadler JE
Hematology Am Soc Hematol Educ Program; 2006; ():415-20. PubMed ID: 17124092
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
15. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M
Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
Mancini I; Ferrari B; Valsecchi C; Pontiggia S; Fornili M; Biganzoli E; Peyvandi F;
Eur J Intern Med; 2017 Apr; 39():79-83. PubMed ID: 27887777
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Lian EC
Semin Thromb Hemost; 2005 Dec; 31(6):625-32. PubMed ID: 16388413
[TBL] [Abstract][Full Text] [Related]
18. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
Zheng XL
Annu Rev Med; 2015; 66():211-25. PubMed ID: 25587650
[TBL] [Abstract][Full Text] [Related]
19. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura.
Westwood JP; Langley K; Heelas E; Machin SJ; Scully M
Br J Haematol; 2014 Mar; 164(6):858-66. PubMed ID: 24372446
[TBL] [Abstract][Full Text] [Related]
20. Interferon-α is not elevated in idiopathic thrombotic thrombocytopenic purpura patients.
Watanaboonyongcharoen P; Whinna HC; Park YA
J Clin Apher; 2014 Dec; 29(6):336-8. PubMed ID: 24764259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
